Temporal trends in the occurrence, mortality, and cost of brain disorders in Denmark

Cecilia Hvitfeldt Fuglsang Nielsen,Thomas Boejer Rasmussen,Jan Haakon Rudolfsen,Jens Olsen,Niels Skipper,Sinna Pilgaard Ulrichsen,Henrik Toft Soerensen,Christian Fynbo Christiansen
DOI: https://doi.org/10.1101/2024.09.18.24313799
2024-09-19
Abstract:Background: Brain disorders, including neurological and mental disorders, are common and burdensome diseases. Aim: To examine temporal trends in occurrence, mortality, and cost of brain disorders in Denmark for the period of 2015-2021. Methods: We conducted a nationwide population-based cohort study using individual-level data recorded in the Danish health registries during 2011-2021. We computed the prevalence of any brain disorder and 25 individual brain disorders for each year from 2015 to 2021 and the incidence for the periods 2011-2015 and 2016-2021 by combining hospital diagnoses and filled prescriptions for relevant medications. We computed one-year hazard ratios (HRs) for mortality by comparing individuals with brain disorders to matched controls without. We also calculated attributable direct and indirect costs (i.e., lost productivity) of brain disorders. Results: The prevalence of any brain disorder in Denmark was 33.2% in 2015, increasing to 35.2% in 2021. The three most prevalent conditions were depression (13.5% in 2021), sleep disorders (13.5% in 2021), and headache (7.9% in 2021). The incidence rate of any brain disorder was 1,792 and 1,634 per 100,000 person-years in 2011-2015 and 2016-2021, respectively. The one-year HR of mortality for any brain disorder was 5.5 (95% confidence internal [CI]: 5.4; 5.6) for 2011-2015 and 5.3 (95% CI: 5.2; 5.3) for 2016-2021. The total attributable direct costs for individuals with any brain disorder were EUR 7.5 billion in both 2015 and 2021. In 2021, the total attributable indirect costs were highest for depression (~EUR 3.5 billion) and lowest for neuromuscular disorders (~EUR 53.5 million). Total indirect costs increased from EUR 17.7 billion in 2015 to EUR 23.2 billion in 2021. In 2021, the total indirect costs were highest for depression (~EUR 14 billion) and lowest for other neurodegenerative disorders (~EUR 60 million). Conclusion: Brain disorders remain common, with a fivefold higher one-year mortality compared to persons without brain disorders. While total direct costs were similar in 2015 and 2021, total indirect costs increased over this period.
What problem does this paper attempt to address?